Evidence map›Paper›PMID 38777940›Full record

ArticleMolecular biology reports2024

Nasal carriage of virulent and multidrug resistant Staphylococcus aureus: a possible comorbidity of COVID-19.

Muinah Adenike Fowora, Adenike Aiyedogbon, Ibilola Omolopo, Ahmed Oluwasegun Tajudeen, Faustina Onyeaghasiri, Idowu Edu-Muyideen, Abdul-Lateef Olatunde Olanlege, Aminah Abioye, Tajudeen Akanji Bamidele, Toyosi Raheem and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. NasalInternational journal of molecular sciences · 2026
    Article
  2. Molecular landscape of methicillin-resistantJAC-antimicrobial resistance · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Muinah Adenike FoworaDepartment of Molecular Biology and Biotechnology, Nigerian Institute of Medical Research, Lagos, Nigeria. muinahj@yahoo.com.ORCID http://orcid.org/0000-0001-7140-2689
Adenike AiyedogbonDepartment of Molecular Biology and Biotechnology, Nigerian Institute of Medical Research, Lagos, Nigeria.ORCID http://orcid.org/0000-0003-1774-0251
Ibilola OmolopoDepartment of Molecular Biology and Biotechnology, Nigerian Institute of Medical Research, Lagos, Nigeria.ORCID http://orcid.org/0000-0003-3276-1173
Ahmed Oluwasegun TajudeenDepartment of Molecular Biology and Biotechnology, Nigerian Institute of Medical Research, Lagos, Nigeria.ORCID http://orcid.org/0000-0002-8002-0145
Faustina OnyeaghasiriFOWM Biotechnology Laboratories, Lagos, Nigeria.ORCID http://orcid.org/0000-0001-7894-7569
Idowu Edu-MuyideenDepartment of Microbiology, Nigerian Institute of Medical Research, Lagos, Nigeria.ORCID http://orcid.org/0009-0008-3436-0318
Abdul-Lateef Olatunde OlanlegeDepartment of Science Laboratory Technology, Faculty of Science, Lagos State University, Lagos, Nigeria.ORCID http://orcid.org/0000-0002-6273-470X
Aminah AbioyeInfectious Diseases Hospital, Lagos, Nigeria.
Tajudeen Akanji BamideleDepartment of Molecular Biology and Biotechnology, Nigerian Institute of Medical Research, Lagos, Nigeria.ORCID http://orcid.org/0000-0003-2155-8639
Toyosi RaheemDepartment of Molecular Biology and Biotechnology, Nigerian Institute of Medical Research, Lagos, Nigeria.ORCID http://orcid.org/0000-0003-1316-3549
Adesegun AdesesanDepartment of Microbiology, Nigerian Institute of Medical Research, Lagos, Nigeria.
Bamidele IwalokunDepartment of Molecular Biology and Biotechnology, Nigerian Institute of Medical Research, Lagos, Nigeria.ORCID http://orcid.org/0000-0003-4247-2797
Babatunde Lawal SalakoDepartment of Molecular Biology and Biotechnology, Nigerian Institute of Medical Research, Lagos, Nigeria.

Funding

Nigerian Institute of Medical Research NMG-CIF-18-0036
6 · The paper itself

Abstract

backgroundStaphylococcus aureus (S. aureus) associated with COVID-19 has not been well documented. This cross-sectional study evaluated the association between nasal S. aureus carriage and COVID-19. METHODS AND

resultsNasopharyngeal samples were collected from 391 participants presenting for COVID-19 test in Lagos, Nigeria, and S. aureus was isolated from the samples. Antimicrobial susceptibility test was done by disc diffusion method. All S. aureus isolates were screened for the presence of mecA, panton-valentine leucocidin (PVL) and toxic shock syndrome toxin (TSST) virulence genes by polymerase chain reaction. Staphylococcal protein A (spa) typing was conducted for all the isolates. Participants with COVID-19 had double the prevalence of S. aureus (42.86%) compared to those who tested negative (20.54%). A significant association was seen between S. aureus nasal carriage and COVID-19 (p = 0.004). Antimicrobial sensitivity results showed resistance to oxacillin (100%), cefoxitin (53%), and vancomycin (98.7%). However, only 41% of the isolates harbored the mecA gene, with SCCmecV being the most common SCCmec type. There was no association between the carriage of virulence genes and COVID-19. A total of 23 Spa types were detected, with t13249 and t095 being the two most common spa types.

conclusionThis study examined the association between nasal S. aureus carriage and SARS-COV-2 infection. Further research is required to fully explore the implications of S. aureus co-infection with COVID-19.

Indexed as

COVID-19SARS-CoV-2Staphylococcal InfectionsStaphylococcus aureusAdultAnti-Bacterial AgentsBacterial ProteinsBacterial ToxinsCarrier StateComorbidityCross-Sectional StudiesDrug Resistance, Multiple, BacterialExotoxinsFemaleHumansLeukocidinsAnti-Bacterial AgentsBacterial ProteinsBacterial ToxinsExotoxinsLeukocidinsmecA protein, Staphylococcus aureusPanton-Valentine leukocidinPenicillin-Binding ProteinsVirulence FactorsCoinfectionCOVID-19S. aureusSCCmecSpa types

Identifiers

PMID38777940

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.